Adipo-X - 120 Liquid Capsules

Adipo-X™ Advanced Fat-Loss Technology - Lose Weight Fast!

Adipo-X™ is the most effective, most innovative, scientifically engineered fat loss formula designed to boost your metabolism, heighten energy levels and improve mental focus and vigor. It uses a liquid capsule delivery system for rapid maximum absorption. Adipo-X™ increases the metabolism safely and naturally with the most unique fat burning formula ever developed. Adipo-X™ destroys fat and lets you get ripped, while allowing you to retain your hard earned muscle.

The key to Adipo-X™’s successful fat loss technology is a multiple pathway approach. Unlike many other weight loss products that try to tackle fat loss through one biochemical pathway or ingredient, Adipo-X™ approaches fat loss in seven different ways.

1. Increases the release of the main adrenal fat loss hormones epinephrine and norepinephrine
2. Enhances the fat loss signal molecule by preventing the messenger molecule cAMP from being broken down
3. Prevents the fat loss hormones from being broken down, which allows the fat loss signal to work continuously
4. Prevents alpha adrenergic receptors from stopping the fat loss process
5. Increases the thermogenic uncoupling process
6. Prevents fat synthesis following meals high in sugar or fat
7. Supports thyroid function

The seven step approach to fat loss makes Adipo-X™ the most effective fat burner developed to date. You haven’t experienced fat loss like this since ephedra. Adipo-X is the perfect addition to your diet and exercise program and it will:

• Maintain lean body mass while burning fat
• Control Appetite and Prevent overeating
• Ramp up energy metabolism (thermogenic)
• Utilize stored body fat as an energy source (lipolysis)
• Support thyroid function and can help increase insulin sensitivity
• Decrease fatigue
• Improve mental focus, clarity and mood

Detailed overview of the multiple steps Adipo-X™ uses to increase fat loss:

The problem with weight loss products that only approach fat loss through one pathway or ingredient is that the body has a way of quickly adapting to any attempt to increase in lipolysis (fat breakdown) or thermogenesis (fat burning). This is called homeostasis, a method of keeping your body in a specific balanced state. Adipo-X™ uses multiple pathways to allow your body to enter a state of continual maximal fat burning. Adipo-X™ turns on the fat burning machinery and keeps you in a fat burning state.

1. Increases the release of the main adrenal fat loss hormones epinephrine and norepinephrine

The ingredients in Adipo-X™ have been scientifically proven to increase the release of the main fat loss hormones epinephrine and norepinephrine. Taking Adipo-X™ turns on the first step in fat loss by causing these hormones to be released. These hormones are known as catecholamines, and they are responsible for the fight or flight (sympathetic) response. These hormones are primarily responsible for activating fat loss in adipose tissue through beta adrenergic stimulation.

2. Enhances the fat loss signal molecule by preventing the messenger molecule cAMP from being broken down

The stimulation of beta adrenergic receptors causes activation of an enzyme that increases levels of a secondary messenger cyclic AMP (cAMP) in fat cells. Increasing cAMP causes an increase in lipolysis (fat release) and thermogeneisis (fat burning) in the fat cells. Cyclic AMP is a very short lived secondary messenger molecule that is broken down by an enzyme called phosphodiesterase (PDE). Adipo-X™ includes ingredients that inhibit PDE and cause an increase in cAMP levels within the cells potentiating the fat loss signal. This allows cAMP to remain active longer, and it allows the fat loss process to continue working.

3. Prevents the fat loss hormones from being broken down, which allows the fat loss signal to work continuously

The fat burning response from Adipo-X™ is further enhanced by preventing the breakdown of the adrenal hormones (norepinephrine and epinephrine). The enzymes COMT (catechol-o-methyltransferase) and MAO (monoamine oxidase) are the primary enzymes that break down these hormones. The ingredients in Adipo-X™ have been clinically shown to inhibit the enzymes COMT and MAO preventing the breakdown of the fat loss hormones. This allow the fat loss signal to work continuously.

4. Prevents alpha adrenergic receptors from stopping the fat loss process

Activation of the alpha adrenergic receptor slows the fat loss process. The ingredients in Adipo-X™ prevent activation of the alpha adrenergic receptor, preventing the fat loss process from slowing down.

5. Increases the thermogenic uncoupling process

The first four steps outlined directly increase the rate of lipolysis (breakdown of fat) in fat cells. The fifth step is activation of thermogenesis in the body. Thermogenesis is the actual process of burning the fat once it has been broken down in the fat cells, and it occurs in the mitochondria of the cell. Thermogenesis turns the broken down fat into energy that your body can use and body heat.

6. Prevents fat synthesis following meals high in sugar or fat

One unique aspect about Adipo-X™ is that it can prevent fat synthesis following meals high in sugar or fat. This is done mainly by molecular interactions with the vanilloid receptor. Adipo-X™ can help keep you on track with your fat loss goals even if you cheat on your diet and indulge in a meal high in sugar or fat.

7. Supports thyroid function

Adipo-X™ has unique ingredients that support thyroid function. The thyroid is the main metabolic regulation center. By properly supporting the thyroid the metabolism is enhanced and fat loss is maximized.

Not taken like any old fat-burner:

How do I take Adipo-X™?
Because Adipo-X™ is a powerful stimulant, we suggest that you start your regimen with a one capsule serving. After assessing your tolerance of the product, increase your serving to two capsules before increasing to three. Take each serving of Adipo-X™ with at least eight ounces of water. Never take more than three capsules in a serving and more than six capsules in a day.

When do I take Adipo-X™?
To complete the thermogenic process, Adipo-X™ contains Capsaicin for its powerful Heat Units. Because of this, Adipo-X™ must be taken on an empty stomach to avoid unsettling. Adipo-X™ is best taken on an empty stomach 30 to 60 minutes before eating breakfast and/or lunch.

It's Time to Begin Your War on Fat!

All of the ingredients in Adipo-X™ work to enhance the body’s ability to burn fat and this will allow you to get that ripped look you’ve been working so hard for. Adipo-X™ works so well at increasing metabolism, thermogenesis and lipolysis that you can actually feel the product working when you take it! A scientifically designed fat loss formula like this has never been developed before. Forget about all the other inefficient weight loss products on the market and upgrade to Axis Labs® Adipo-X™. Get Adipo-X™ now to help you expose your hardest core ever!

Demand more from your fat burner. Demand Axis Labs®.

Other Ingredients: Gelatin, Lecithin and Mixed Tocopherols.

Directions: As a dietary supplement, start with a 1 capsule serving to evaluate tolerance and gradually increase to a full 3 capsule serving. Take one serving with 8 oz of water 30 to 60 minutes prior to breakfast on an empty stomach and an additional serving in the early afternoon on an empty stomach. Do not exceed 6 capsules in a 24 hour period. Do not take 6 hours prior to bed because ADIPO-X™ may interfere with sleep. Read entire label before using. For even better results, stack with Axis Labs® SesaMAX®.

Store in a cool place. Protect from heat, light and moisture.

WARNING: KEEP OUT OF REACH OF CHILDREN. Not for use by individuals under the age of 18 or elderly. Consult a physician before using this or any dietary supplement. Do not use if pregnant, nursing or chronically ill. This product is not intended for individuals who are at risk of or have been treated for digestive disorders, high blood pressure, heart disease, thyroid disease, depression or other psychiatric conditions, renal disease, reoccurring headaches, spasms, has asthma or taking asthma medication or if your are using a MAO inhibitor.

Manufactured with pride in the USA.
Adipo-X™ is a registered trademark of Axis Labs®.

* These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease.

References:

Akiba, T., K. Yaguchi, et al. (2004). "Inhibitory mechanism of caffeine on insulin-stimulated glucose uptake in adipose cells." Biochem Pharmacol 68(10): 1929-37.
Banderet, L. E. and H. R. Lieberman (1989). "Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans." Brain Res Bull 22(4): 759-62.
Belza, A., E. Frandsen, et al. (2007). "Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects." Int J Obes (Lond) 31(1): 121-30.
Bhardwaj, R. K., H. Glaeser, et al. (2002). "Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4." J Pharmacol Exp Ther 302(2): 645-50.
Borea, P. A., K. Varani, et al. (1994). "Full and partial agonistic behaviour and thermodynamic binding parameters of adenosine A1 receptor ligands." Eur J Pharmacol 267(1): 55-61.
Carlson, L. A., R. W. Butcher, et al. (1970). "Fat mobilizing lipolysis and levels of cyclic AMP in human and dog adipose tissue." Acta Med Scand 187(6): 525-8.
Chanadiri, T., T. Sanikidze, et al. (2005). "[Effectiveness of green tea catechines for the correction of the alimentary obesity in the experiment]." Georgian Med News(126): 61-3.
Chaudhry, A. and J. G. Granneman (1991). "Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat." Am J Physiol 261(2 Pt 2): R403-11.
Chaudhry, A. and J. G. Granneman (1997). "Effect of hypothyroidism on adenylyl cyclase activity and subtype gene expression in brown adipose tissue." Am J Physiol 273(2 Pt 2): R762-7.
Chen, D., C. Y. Wang, et al. (2005). "Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies." Biochem Pharmacol 69(10): 1523-31.
Choi, H. S. (2006). "Lipolytic effects of citrus peel oils and their components." J Agric Food Chem 54(9): 3254-8.
Cui, J. and J. Himms-Hagen (1992). "Long-term decrease in body fat and in brown adipose tissue in capsaicin-desensitized rats." Am J Physiol 262(4 Pt 2): R568-73.
Currie, P. J. and L. M. Wilson (1992). "Yohimbine attenuates clonidine-induced feeding and macronutrient selection in genetically obese (ob/ob) mice." Pharmacol Biochem Behav 43(4): 1039-46.
Diepvens, K., E. M. Kovacs, et al. (2005). "Effect of green tea on resting energy expenditure and substrate oxidation during weight loss in overweight females." Br J Nutr 94(6): 1026-34.
Diepvens, K., K. R. Westerterp, et al. (2007). "Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea." Am J Physiol Regul Integr Comp Physiol 292(1): R77-85.
Dolgacheva, L. P., B. B. Abzhalelov, et al. (2003). "Norepinephrine induces slow calcium signalling in murine brown preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway." Cell Signal 15(2): 209-16.
Dulloo, A. G., C. Duret, et al. (1999). "Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans." Am J Clin Nutr 70(6): 1040-5.
Dulloo, A. G., J. Seydoux, et al. (2000). "Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity." Int J Obes Relat Metab Disord 24(2): 252-8.
Galitzky, J., M. Lafontan, et al. (1993). "Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue." J Clin Invest 91(5): 1997-2003.
Galitzky, J., D. Riviere, et al. (1990). "Pharmacodynamic effects of chronic yohimbine treatment in healthy volunteers." Eur J Clin Pharmacol 39(5): 447-51.
Galitzky, J., M. Taouis, et al. (1988). "Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers." Eur J Clin Invest 18(6): 587-94.
Gelenberg, A. J., C. J. Gibson, et al. (1982). "Neurotransmitter precursors for the treatment of depression." Psychopharmacol Bull 18(1): 7-18.
Gomez-Ambrosi, J., G. Fruhbeck, et al. (2001). "Divergent effects of an alpha2-adrenergic antagonist on lipolysis and thermogenesis: interactions with a beta3-adrenergic agonist in rats." Int J Mol Med 8(1): 103-9.
Grunfeld, C. and J. K. Shigenaga (1984). "Nicotinamide and other inhibitors of ADP-ribosylation block deoxyglucose uptake in cultured cells." Biochem Biophys Res Commun 123(2): 785-91.
Han, L. K., X. J. Gong, et al. (2005). "[Antiobesity actions of Zingiber officinale Roscoe]." Yakugaku Zasshi 125(2): 213-7.
Harmer, C. J., S. F. McTavish, et al. (2001). "Tyrosine depletion attenuates dopamine function in healthy volunteers." Psychopharmacology (Berl) 154(1): 105-11.
Hellstrom, L., S. Rossner, et al. (1997). "Lipolytic catecholamine resistance linked to alpha 2-adrenoceptor sensitivity--a metabolic predictor of weight loss in obese subjects." Int J Obes Relat Metab Disord 21(4): 314-20.
Ho, R. and Q. H. Shi (1982). "Forskolin as a novel lipolytic agent." Biochem Biophys Res Commun 107(1): 157-64.
Ho, R. J. (1970). "Dependence of hormone-stimulated lipolysis on ATP and cyclic AMP levels in fat cells." Horm Metab Res 2: Suppl 2:83-7.
Honnor, R. C., G. S. Dhillon, et al. (1985). "cAMP-dependent protein kinase and lipolysis in rat adipocytes. II. Definition of steady-state relationship with lipolytic and antilipolytic modulators." J Biol Chem 260(28): 15130-8.
Howald, H. and J. Decombaz (1983). "Nutrient intake and energy regulation in physical exercise." Experientia Suppl 44: 77-88.
Imbeault, P., D. Prud'Homme, et al. (2000). "Adipose tissue metabolism in young and middle-aged men after control for total body fatness." J Clin Endocrinol Metab 85(7): 2455-62.
Imbeault, P., A. Tremblay, et al. (2000). "beta-adrenoceptor-stimulated lipolysis of subcutaneous abdominal adipocytes as a determinant of fat oxidation in obese men." Eur J Clin Invest 30(4): 290-6.
Kawada, T., K. Hagihara, et al. (1986). "Effects of capsaicin on lipid metabolism in rats fed a high fat diet." J Nutr 116(7): 1272-8.
Kawada, T., T. Watanabe, et al. (1986). "Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization." Proc Soc Exp Biol Med 183(2): 250-6.
Kirchgessner, M., D. A. Roth-Maier, et al. (1995). "[B-vitamins (thiamine, vitamin b6, pantothenic acid) in lean muscle tissue of growing cattle of the German Simmental breed under different feeding intensities]." Z Lebensm Unters Forsch 201(1): 20-4.
Kobayashi, A., T. Osaka, et al. (1998). "Capsaicin activates heat loss and heat production simultaneously and independently in rats." Am J Physiol 275(1 Pt 2): R92-8.
Kucio, C., K. Jonderko, et al. (1991). "Does yohimbine act as a slimming drug?" Isr J Med Sci 27(10): 550-6.
Lambert, J. D., J. Hong, et al. (2004). "Piperine enhances the bioavailability of the tea polyphenol (-)-epigallocatechin-3-gallate in mice." J Nutr 134(8): 1948-52.
Le Corre, P., G. Dollo, et al. (1999). "Biopharmaceutics and metabolism of yohimbine in humans." Eur J Pharm Sci 9(1): 79-84.
Lejeune, M. P., E. M. Kovacs, et al. (2003). "Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects." Br J Nutr 90(3): 651-59.
Lemonnier, D., P. de Gasquet, et al. (1974). "Effect of dietary vitamin B level on fat storage, adipose tissue cellularity and energy expenditure in rats and mice fed a high-fat diet." Nutr Metab 16(1): 15-29.
Lieberman, H. R., J. H. Georgelis, et al. (2005). "Tyrosine prevents effects of hyperthermia on behavior and increases norepinephrine." Physiol Behav 84(1): 33-8.
Lin, Z., Y. Liao, et al. (2007). "Amides from Piper nigrum L. with dissimilar effects on melanocyte proliferation in-vitro." J Pharm Pharmacol 59(4): 529-36.
Litosch, I., T. H. Hudson, et al. (1982). "Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes." Mol Pharmacol 22(1): 109-15.
Lu, H., X. Meng, et al. (2003). "Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate." Drug Metab Dispos 31(5): 572-9.
Malbon, C. C. and M. P. Graziano (1983). "Adenosine deaminase normalizes cyclic AMP responses of hypothyroid rat fat cells to forskolin, but not beta-adrenergic agonists." FEBS Lett 155(1): 35-8.
Masuda, Y., S. Haramizu, et al. (2003). "Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog." J Appl Physiol 95(6): 2408-15.
McNamara, F. N., A. Randall, et al. (2005). "Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1)." Br J Pharmacol 144(6): 781-90.
Melnyk, A. and J. Himms-Hagen (1995). "Resistance to aging-associated obesity in capsaicin-desensitized rats one year after treatment." Obes Res 3(4): 337-44.
Mochizuki, M. and N. Hasegawa (2004). "Effects of green tea catechin-induced lipolysis on cytosol glycerol content in differentiated 3T3-L1 cells." Phytother Res 18(11): 945-6.
Morimoto, C., Y. Satoh, et al. (2005). "Anti-obese action of raspberry ketone." Life Sci 77(2): 194-204.
Muroyama, K., S. Murosaki, et al. (2003). "Effects of intake of a mixture of thiamin, arginine, caffeine, and citric acid on adiposity in healthy subjects with high percent body fat." Biosci Biotechnol Biochem 67(11): 2325-33.
Muroyama, K., S. Murosaki, et al. (2003). "Anti-obesity effects of a mixture of thiamin, arginine, caffeine, and citric acid in non-insulin dependent diabetic KK mice." J Nutr Sci Vitaminol (Tokyo) 49(1): 56-63.
Ohnuki, K., S. Haramizu, et al. (2001). "Administration of capsiate, a non-pungent capsaicin analog, promotes energy metabolism and suppresses body fat accumulation in mice." Biosci Biotechnol Biochem 65(12): 2735-40.
Ostman, J. (1964). "Effect Of Nicotinic Acid On The Fatty Acid Metabolism Of Adipose Tissue In Alloxan Diabetic Rats." Metabolism 13: 675-80.
Ostman, J. (1965). "Inhibitory Effect Of Nicotinic Acid On Fat Mobilization In Alloxan-Diabetic Rats. Ii. A Comparison Of The Effect Of Nicotinic Acid And Salicylate On The Fatty Acid Metabolism And Glucose Uptake By Adipose Tissue In Vitro." Acta Med Scand 177: 623-9.
Papadelis, C., C. Kourtidou-Papadeli, et al. (2003). "Effects of mental workload and caffeine on catecholamines and blood pressure compared to performance variations." Brain Cogn 51(1): 143-54.
Rababah, T. M., N. S. Hettiarachchy, et al. (2004). "Total phenolics and antioxidant activities of fenugreek, green tea, black tea, grape seed, ginger, rosemary, gotu kola, and ginkgo extracts, vitamin E, and tert-butylhydroquinone." J Agric Food Chem 52(16): 5183-6.
Razzoli, G. (1972). "[Effect of coffee on deposit lipids]." Minerva Med 63(61): 3361-2.
Roberts, S. A., J. M. Thorpe, et al. (2001). "Tyrosine requirement of healthy men receiving a fixed phenylalanine intake determined by using indicator amino acid oxidation." Am J Clin Nutr 73(2): 276-82.
Scarpace, P. J., L. A. Baresi, et al. (1987). "Modulation of receptors and adenylate cyclase activity during sucrose feeding, food deprivation, and cold exposure." Am J Physiol 253(6 Pt 1): E629-35.
Schimmel, R. J. (1980). "Interactions between catecholamines, methyl xanthines and adenosine in regulation of cyclic AMP accumulation in hamster adipocytes." Biochim Biophys Acta 629(1): 83-94.
Shixian, Q., B. VanCrey, et al. (2006). "Green tea extract thermogenesis-induced weight loss by epigallocatechin gallate inhibition of catechol-O-methyltransferase." J Med Food 9(4): 451-8.
Simon, E., M. T. Macarulla, et al. (2005). "Body fat-lowering effect of conjugated linoleic acid is not due to increased lipolysis." J Physiol Biochem 61(2): 363-9.
Srinivasan, M. R. and M. N. Satyanarayana (1989). "Effect of capsaicin on skeletal muscle lipoprotein lipase in rats fed high fat diet." Indian J Exp Biol 27(10): 910-2.
Szallasi, A. (2005). "Piperine: researchers discover new flavor in an ancient spice." Trends Pharmacol Sci 26(9): 437-9.
Szilagyi, G., Z. Nagy, et al. (2005). "Effects of vinpocetine on the redistribution of cerebral blood flow and glucose metabolism in chronic ischemic stroke patients: a PET study." J Neurol Sci 229-230: 275-84.
Tam, S. W., M. Worcel, et al. (2001). "Yohimbine: a clinical review." Pharmacol Ther 91(3): 215-43.
Tapsell, L. C., I. Hemphill, et al. (2006). "Health benefits of herbs and spices: the past, the present, the future." Med J Aust 185(4 Suppl): S4-24.
Tornqvist, H., L. Krabisch, et al. (1972). "Rapid assay for hormone-sensitive lipase activity of adipose tissue." J Lipid Res 13(3): 424-6.
Tsi, D., A. K. Nah, et al. (2003). "Clinical study on the combined effect of capsaicin, green tea extract and essence of chicken on body fat content in human subjects." J Nutr Sci Vitaminol (Tokyo) 49(6): 437-41.
Verma, S. K. and A. Bordia (2001). "Ginger, fat and fibrinolysis." Indian J Med Sci 55(2): 83-6.
Walldius, G. and G. Wahlberg (1985). "Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis." Adv Exp Med Biol 183: 281-93.
Westerterp-Plantenga, M., K. Diepvens, et al. (2006). "Metabolic effects of spices, teas, and caffeine." Physiol Behav 89(1): 85-91.
Wolfram, S., Y. Wang, et al. (2006). "Anti-obesity effects of green tea: from bedside to bench." Mol Nutr Food Res 50(2): 176-87.
Wu, A. H., C. C. Tseng, et al. (2003). "Tea intake, COMT genotype, and breast cancer in Asian-American women." Cancer Res 63(21): 7526-9.
Yoshida, T., K. Yoshioka, et al. (1988). "Effects of capsaicin and isothiocyanate on thermogenesis of interscapular brown adipose tissue in rats." J Nutr Sci Vitaminol (Tokyo) 34(6): 587-94.
Zhang, L. L., D. Yan Liu, et al. (2007). "Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity." Circ Res 100(7): 1063-70.